Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elekta ABEKTAY -3.32%75 Debt-to-Equity is 0.90 as of Jul. 2026, which is 18% above its 10-year median of 0.76. GuruFocus rates EKTAY with a GF Score™ of 75/100 and a GF Value™ of $6.49 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 697 Medical Devices & Instruments companies, Elekta AB ranks worse than 85.94% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Elekta AB's Debt-to-Equity or its related term are showing as below:
EKTAY'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.59 Med: 0.76 Max: 1.15
Current: 1.03
During the past 13 years, the highest Debt-to-Equity Ratio of Elekta AB was 1.15. The lowest was 0.59. And the median was 0.76.
EKTAY's Debt-to-Equity is ranked worse than 85.94% of 697
companies
in the Medical Devices & Instruments industry
Industry Median: 0.24
vs EKTAY: 1.03
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Elekta AB Debt-to-Equity Related Terms
Elekta AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Elekta AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Elekta AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elekta AB Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Elekta AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Elekta AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elekta AB (EKTAY) has a Debt-to-Equity of 0.90 as of Jul. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Elekta AB and its competitors. This is 18% above median its historical median of 0.76. Over the past decade, Elekta AB's Debt-to-Equity has ranged from 0.59 to 1.15. According to the industry distribution chart, Elekta AB ranks #599 out of 697 companies in the Medical Devices & Instruments industry, placing it in the top 85.9%.
Is Elekta AB's Debt-to-Equity too high?
Elekta AB's current Debt-to-Equity of 0.90 is 18% above median its 10-year median of 0.76. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 1.15. The Medical Devices & Instruments industry median Debt-to-Equity is 0.24. Elekta AB's value of 0.90 is 275% above this industry median. Based on the distribution chart, Elekta AB ranks #599 out of 697 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Elekta AB has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Elekta AB's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Elekta AB ranks #599 out of 697 companies for Debt-to-Equity. This places Elekta AB in the lower half of its industry. The industry median Debt-to-Equity is 0.24. Elekta AB's value of 0.90 is 275% above this benchmark. Historically, Elekta AB's own Debt-to-Equity has ranged from 0.59 to 1.15 over the past decade. While the company's 10-year median is 0.76 vs. the industry median of 0.24, Elekta AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 697 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elekta AB's current Debt-to-Equity of 0.90 is 275% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Elekta AB and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elekta AB's current Debt-to-Equity is 0.90, which is 18% above median its own 10-year median of 0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elekta AB stock overvalued right now?
Based on GuruFocus' analysis, Elekta AB (EKTAY) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.49, compared to a current price of $5.50 — trading 15.3% below its estimated fair value. The current Debt-to-Equity is 0.90, which is 18% above median its 10-year median of 0.76 and 275% above the Medical Devices & Instruments industry median of 0.24. Elekta AB's overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Elekta AB (EKTAY), the current Debt-to-Equity is 0.90 as of Jul. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elekta AB (EKTAY) Overvalued in 2026?
Based on GuruFocus' analysis, Elekta AB stock appears to be undervalued.
The current stock price of $5.50 is trading 15.3% below its estimated GF Value™ of $6.49.
GuruFocus considers Elekta AB to be Modestly Undervalued.
Key valuation signals for EKTAY:
Debt-to-Equity: 0.90 (18% above median its 10-year median of 0.76)
GF Value™: $6.49 vs. price of $5.50 (15.3% below fair value)
Industry Position: 275% above the Medical Devices & Instruments median (#599 of 697)
No single metric tells the full story. See the EKTAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sweden-based Elekta develops, manufactures, and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy. The company has an installed base of more than 7,300 linear accelerators, Gamma Knife and Unity platforms, as well as brachytherapy installations. The company's sales are evenly distributed across geographies, with North and South America accounting for 29%; Europe, the Middle East, and Africa accounting for 37%; and the Asia-Pacific contributing the remainder.
75GF Score
Get the complete analysis for EKTAY
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EKTAY has been successfully added to your 
